Skip to main content
. 2016 Jul 25;6:30085. doi: 10.1038/srep30085

Figure 4. α2A-adrenoreceptor mediates the short-term pro-catabolic effects of norepinephrine.

Figure 4

(A) Real-time PCR of the expression of aggrecan, MMP-3, MMP-13 and RANKL by chondrocytes after NE stimulation combined with different inhibitors of adrenoreceptors and pathways (N = 5). Chondrocytes were stimulated by 10−7 M NE for 1 h alone, or pre-treated for 1 h with 10−5 M doxazosin (Dox, α1-adrenoreceptor antagonist), yohimbine (Yoh, α2-adrenoreceptor antagonist), propranolol (Pro, β-adrenoreceptor antagonist), ICI 118,551 (ICI, β2-adrenoreceptor antagonist), U0126 (ERK1/2 inhibitor), SP600125 (SP, JNK inhibitor), SB203580 (SB, p38 inhibitor) or LY294002 (LY, AKT inhibitor). (B,C) Western blot of the expression of aggrecan, MMP-3, MMP-13 and RANKL by chondrocytes after NE stimulation combined with yohimbine (Yoh), U0126 or LY294002 (LY) treatment (N = 3). *P < 0.05, **P < 0.01: vs vehicle-treated chondrocytes; #P < 0.05, ##P < 0.01: vs the corresponding NE-treated chondrocytes.